Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Symphony Financial Ltd. Co.

Symphony Financial Ltd. Co. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,337 shares of the biopharmaceutical company’s stock after purchasing an additional 1,580 shares during the period. Symphony Financial Ltd. Co.’s holdings in Gilead Sciences were worth $611,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Tompkins Financial Corp boosted its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC acquired a new position in Gilead Sciences during the 4th quarter valued at about $29,000. Private Wealth Management Group LLC bought a new position in Gilead Sciences in the 4th quarter worth about $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GILD. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a report on Friday, June 14th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Barclays reduced their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. TD Cowen lowered their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Maxim Group reduced their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $83.47.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $0.22 during midday trading on Friday, reaching $68.61. The company’s stock had a trading volume of 9,590,049 shares, compared to its average volume of 9,497,302. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average price of $65.98 and a 200 day moving average price of $72.58. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The company has a market cap of $85.48 billion, a price-to-earnings ratio of 190.58, a price-to-earnings-growth ratio of 2.92 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the firm earned $1.37 EPS. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.